Safety of brigatinib following alectinib-induced-pneumonitis: Case report
Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK TKIs) show robust efficacy and has revolutionized the treatment of NSCLC patients harboring an ALK-rearrangement. Side effects, sometimes even serious such as pneumonitis, can occur with ALK TKIs.We report a case of a patient with ALK positi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Respiratory Medicine Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007124001837 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823864385925283840 |
|---|---|
| author | Blerina Resuli Heidi Galarza Laura Elsner Diego Kauffmann-Guerrero Jürgen Behr Amanda Tufman |
| author_facet | Blerina Resuli Heidi Galarza Laura Elsner Diego Kauffmann-Guerrero Jürgen Behr Amanda Tufman |
| author_sort | Blerina Resuli |
| collection | DOAJ |
| description | Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK TKIs) show robust efficacy and has revolutionized the treatment of NSCLC patients harboring an ALK-rearrangement. Side effects, sometimes even serious such as pneumonitis, can occur with ALK TKIs.We report a case of a patient with ALK positive advanced NSCLC who developed pneumonitis during treatment with first-line alectinib. With no alternative etiology of pneumonitis identified, the patient was treated with corticosteroids and discontinuation of alectinib. Following rapid clinical recovery and radiographic resolution of the opacities, the patient was started with brigatinib, with no recurrence of the clinical symptoms or radiographic findings of pneumonitis. While further descriptions are needed, our experience suggests that switching to a second ALK-TKI may be a safe therapeutic option in some patients who develop drug-induced pneumonitis on ALK TKIs. |
| format | Article |
| id | doaj-art-35fb2df8e7004331a253992864a5926b |
| institution | Kabale University |
| issn | 2213-0071 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Respiratory Medicine Case Reports |
| spelling | doaj-art-35fb2df8e7004331a253992864a5926b2025-02-09T05:00:20ZengElsevierRespiratory Medicine Case Reports2213-00712025-01-0153102160Safety of brigatinib following alectinib-induced-pneumonitis: Case reportBlerina Resuli0Heidi Galarza1Laura Elsner2Diego Kauffmann-Guerrero3Jürgen Behr4Amanda Tufman5Department of Medicine V, LMU University Hospital, LMU Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), Germany; Corresponding author. Department of Internal Medicine V, Thoracic Oncology Centre, Ludwig-Maximilians-Universität, Ziemssenstraße 1, 80336, München, Germany.Department of Medicine V, LMU University Hospital, LMU Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), GermanyDepartment of Medicine V, LMU University Hospital, LMU Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), GermanyDepartment of Medicine V, LMU University Hospital, LMU Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), GermanyDepartment of Medicine V, LMU University Hospital, LMU Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), GermanyDepartment of Medicine V, LMU University Hospital, LMU Munich, Germany; Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), GermanyAnaplastic lymphoma kinase tyrosine kinase inhibitors (ALK TKIs) show robust efficacy and has revolutionized the treatment of NSCLC patients harboring an ALK-rearrangement. Side effects, sometimes even serious such as pneumonitis, can occur with ALK TKIs.We report a case of a patient with ALK positive advanced NSCLC who developed pneumonitis during treatment with first-line alectinib. With no alternative etiology of pneumonitis identified, the patient was treated with corticosteroids and discontinuation of alectinib. Following rapid clinical recovery and radiographic resolution of the opacities, the patient was started with brigatinib, with no recurrence of the clinical symptoms or radiographic findings of pneumonitis. While further descriptions are needed, our experience suggests that switching to a second ALK-TKI may be a safe therapeutic option in some patients who develop drug-induced pneumonitis on ALK TKIs.http://www.sciencedirect.com/science/article/pii/S2213007124001837AlectinibBrigatinibNSCLCPneumonitisCase report |
| spellingShingle | Blerina Resuli Heidi Galarza Laura Elsner Diego Kauffmann-Guerrero Jürgen Behr Amanda Tufman Safety of brigatinib following alectinib-induced-pneumonitis: Case report Respiratory Medicine Case Reports Alectinib Brigatinib NSCLC Pneumonitis Case report |
| title | Safety of brigatinib following alectinib-induced-pneumonitis: Case report |
| title_full | Safety of brigatinib following alectinib-induced-pneumonitis: Case report |
| title_fullStr | Safety of brigatinib following alectinib-induced-pneumonitis: Case report |
| title_full_unstemmed | Safety of brigatinib following alectinib-induced-pneumonitis: Case report |
| title_short | Safety of brigatinib following alectinib-induced-pneumonitis: Case report |
| title_sort | safety of brigatinib following alectinib induced pneumonitis case report |
| topic | Alectinib Brigatinib NSCLC Pneumonitis Case report |
| url | http://www.sciencedirect.com/science/article/pii/S2213007124001837 |
| work_keys_str_mv | AT blerinaresuli safetyofbrigatinibfollowingalectinibinducedpneumonitiscasereport AT heidigalarza safetyofbrigatinibfollowingalectinibinducedpneumonitiscasereport AT lauraelsner safetyofbrigatinibfollowingalectinibinducedpneumonitiscasereport AT diegokauffmannguerrero safetyofbrigatinibfollowingalectinibinducedpneumonitiscasereport AT jurgenbehr safetyofbrigatinibfollowingalectinibinducedpneumonitiscasereport AT amandatufman safetyofbrigatinibfollowingalectinibinducedpneumonitiscasereport |